plant inspection. The US FDA inspected Aurobindo Pharma's Unit-XII facility at Bachupally, Telangana from August 25 to September 5, 2025. An FDA Form 483 with eight procedural observations was issued, but Aurobindo said these do not impact its financials or operations. A response will be submitted within required timelines. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.

#TrendingSectors

632 likes·61 comments